Insilico Medicine, Inc.

ROCKVILLE, MD · Founded 2014 · CIK 0001698493 · Biotech · Public

AI platform for drug discovery and longevity research using generative models and machine learning

insilico.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$20M
3 Form D · Jun 2018
100 months since last filing
Contracts
—
No federal contracts on record
Patents
23
7 granted · 16 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$9,998,988
Private capital raisedForm D · SEC$4,000,000
Private capital raisedForm D · SEC$5,999,950
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2524ASSAYQUANT TECHNOLOGIES, INC.—$9.6M
2525Sonata Biosciences Inc——
2526GENTEL BIOSCIENCES INC—$2.7M
2527Insilico Medicine, Inc.—$20M
2528Nuvectis Pharma, Inc.—$16M
2529ImmuneBridge Inc.—$16M
2530IpiNovyx Bio, Inc.—$7.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • James MellonDirector
  • Aleksandrs ZavoronkovsDirector · Executive Officer
  • Alex ZhavoronkovDirector · Executive Officer
  • Qingsong ZhuExecutive Officer

Patents

USPTO · 7 granted of 23

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.